Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

JAK/STAT

  • You have access
    CJ14939, a Novel JAK Inhibitor, Increases Oxaliplatin-induced Cell Death Through JAK/STAT Pathway in Colorectal Cancer
    JUN KI HONG, DO YEON KIM, JAE-SIK SHIN, YEA SEONG RYU, JAI-HEE MOON, DONG-IN KOH, SEUL LEE, JINWOO LEE, WON JUN LEE, EUN YOUNG LEE, SOO-A JUNG, SEUNG CHAN KIM, HA NA YU, MI JIN KIM, SEUNG-WOO HONG, SANG SOO PARK, JOONYEE JUNG, SEUNG MI KIM, EUN HO KIM, HONG-RAE JEONG, JI HEE GONG, JIEUN KIM, TAE WON KIM and DONG-HOON JIN
    Anticancer Research April 2022, 42 (4) 1813-1819; DOI: https://doi.org/10.21873/anticanres.15657
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire